Sono, Sailing, Scorekeeper, Kursorrie....
Kursorrie last posted that he knew how long of a commute LS had. (back in Sep 2013 when he established his new alias...so the disgruntled employee theory still rings true for this person) Either all of these people are the same person who try to bait others for responses or both of them work in adjoining cubicles. Sad....
I have to disagree with you here. CMS did the right thing on payment. The market requires another method for screening...more choice is always better.
But the question remains if people will use/request it over other tests or simply go straight to colonoscopy - which is still the gold standard. I seriously doubt that the general public understands sensitivity and specificity to the degree that all of you do. (We will know with a few quarters if this is the monster that Wall Street has made it out to be - no company can hide from their own numbers.)
And I am also scheduling my colonoscopy for 2015. This company has been good about Colon Cancer awareness evidenced by the longer waiting lines for the scope.
And for disclosure, I have not taken a FIT/ FOBT/ or other Genetic CC test.
Sono...are you OK? ...you have only posted once today! Why are you picking on MO? Ideas flow from contributions, not bashing.
As I recall, it was you who started all the LS bashing, about the same time you freaked out that DPP HIV would never get CLIA Waiver. Turn over a new leaf...get a new ID and help build this company. Contribute to the discussion...what's hot and emerging other than ebola? They do read the message board.
If LS' plan is to get to 3% holding, then he has 200,000 shares yet to sell. No matter how you dice the news from last week, it was all positive. 1 more week of selling in my viewpoint.
Sure...Ebola would make headlines and makes sense with the already developed Febrile panel. But for Maximum impact:
But HIV-Syphilis puts Chembio on everyone’s top investment pick. EVERY hospital lab in America is trying to put Syphilis on their testing menu and each large diagnostic company has plans to develop an automated Syphilis test for their instruments. (this requires CLIA Moderately Complex status only). Public health needs the CLIA Waiver. This is a first to market game changer.
HIV-Syphilis is a killer application for DPP. Chembio has a strong future.
Sentiment: Strong Buy
I noticed that IT has attempted to respond 3 or 4 more times to something. I would encourage him to stay on this board if has something valuable to share or if he thinks we should be shorting CEMI, like I will be shorting EXAS. I would love to know his reasons...on EXAS he knows mine.
Saw this headline today which should bode well for all diagnostic kit manufacturers....in particular Chembio. Also, in speaking with laboratory professionals this week, they all would like a Flu A/B test that can also detect various febrile diseases like Ebola and Malaria. In larger health care systems, even in more rural areas, they get patients with recent travel to Africa. Imagine all the concern over Ebola during this flu season...
It will take longer than 4 years to gain complete physician acceptance of this test. And understanding that other genetic tests haven’t pushed out FIT and FOBT yet, neither will Cologuard. Great test. Hopefully the company can continue to raise more cash for this long launch and future products.
Sentiment: Strong Buy
Hi Sailing and Sono:
With all due respect, there is nothing to gain from your contributions on this message board. We have CLIA Waiver, multiple live projects, grant awards, research projects, and royalty streams. This is all just a beginning. All of us old timers are in the money...and all of my concerns with Chembio evaporated when CLIA Waiver came through. DPP is next generation rapid diagnostic testing.
I have a deep respect for Larry Siebert for his vision and his timing of stepping aside for a great commercial CEO in JS. (Regardless of your “feelings,” there would be no Chembio if LS wasn’t involved.) I am curious about LS’ new position as a Senior M&A advisor for diagnostics. My guess is that he is still involved with shareholder value at Chembio.
See you from time to time...probably on the EXAS board. Long live the longs!
Sentiment: Strong Buy
Sono...don’t forget royalty payments. The Biorad Geenius HIV Confirmatory test appears to be a complete replacement of Western Blot confirmatory testing. I would not be surprised to see guidelines call this test the new gold standard soon.
Chart - completely agree! If anyone had a concern about Chembio’s future before, they should have none now. The CLIA Waiver was the last overhang. Lots of work to be done to be sure, but all the doors have been opened.
Sono - Yeah, I am an ignoramus...sure. Several rapid tests in EU are coming to the forefront. Another one announced recently comes with the backing of Scientists from the French Atomic Energy Commission (CEA). They teamed up with pharma company Vedalab for an Ebola 15 min rapid test. This would be a small lateral flow test paired with a hand-held device.
With Ebola testing, the only advantage Orasure and Chembio will have is the ability to test with oral samples.
pilo: Don't tread on those attempting to make Wisconsin Stronger...you have no idea what you are talking about.
Ah Sailing...you are in love with your EXAS. I have mentioned before that I agree with the pieces of data you represent. Be good to yourself and have a plan when EXAS reverses. It’s a $2+ Billion MCap with no sales (By comparison, Quest, who also has a non-invasive molecular Colon Cancer test is only valued around $8 Billion). You don’t seem to be good with math...so never mind.